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Objective: This study determined the incidence and characteristics of recurrent disease after femoropopliteal angioplasty,
following either selective or routine stenting of diseased site(s).
Methods: Retrospective analysis of a prospectively maintained database for femoropopliteal interventions from June 2003
to July 2010 was performed. Interventions during this period were from a single institution, followed up at 1, 3, and 6
months after initial intervention and on a semiannual basis thereafter with clinical examinations and duplex ultrasound
imaging. Two groups were identified: those with routine stenting (RS; routine stenting for all diseased areas) and those
with selective stenting (SS; selective stenting for only segments which exhibited compromised flow from residual stenosis
or significant dissection). Patients who developed recurrent symptoms (claudication, rest pain), a decrease in ankle-
brachial index (ABI) (>0.2), or duplex documentation of a significant (>80%) recurrent stenosis underwent reinterven-
tion. Patient demographics, comorbidities, Trans-Atlantic Inter-Society Consensus (TASC) II classification, runoff, and
degree of calcification (none, mild, moderate, severe) at initial intervention were recorded. The time to reintervention and
recurrence pattern were recorded for both groups.
Results: During the study period, 746 endovascular interventions in 477 patients were performed. Total reintervention
rate, including bypass, amputation, and asymptomatic occlusion after initial intervention, was 36.48% (group SS, 42.9%;
group RS, 33.1%; P  .04). Of all initial interventions, 182 endovascular reinterventions in 165 patients for recurrent
femoropopliteal disease were identified (group SS, 70; group RS, 95). No differences were noted among the groups in
gender, comorbidities, initial TASC II classification, run off, calcification scores, or statin or clopidogrel use, or both.
Time to recurrence was similar in the RS and SS groups. TASC II classification, runoff score, and degree of calcification
were similar between the two groups. Although not statistically significant, analysis of recurrence pattern demonstrated
de novo stenosis was more common in the SS group (50.0% vs 34.7%; P  .06).
Conclusions: This single-center retrospective study found a significant difference in the incidence of recurrence requiring
reintervention between patients treated with selective and routine stenting for femoropopliteal disease. Analysis of
endovascular reinterventions, however, reveals no significant difference in recurrence time or recurrence pattern between
the two groups. No significant differences were identified in time to recurrence, TASC II classification, runoff, and
calcification of endovascular reinterventions between the two groups’ end points. Additional prospective studies to
evaluate the roles of routine and selective stenting in symptomatic femoropopliteal peripheral arterial disease and to
investigate recurrence lesion characteristics and the patency of multiple endovascular interventions between these two



















sPeripheral arterial disease (PAD) affects 10 million
patients in the United States.1 The superficial femoral
artery (SFA) is extremely vulnerable to atherosclerotic dis-
ease due to its location and function. Patients with occlu-
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http://dx.doi.org/10.1016/j.jvs.2012.06.097ive disease in this artery can experience symptoms ranging
rom intermittent claudication and slow-to-heal lower ex-
remity ulcers to critical limb ischemia.2 Conservative man-
gement strategies to slow the progression of PAD involve
isk factor modification, including smoking cessation, op-
imized glycemic control, treatment of dyslipidemia and
ypertension, exercise therapy, and use of pharmacologic
gents such as cilostazol or pentoxifylline.3,4 Best medical
reatment strategies have demonstrated limited success in
esolving PAD symptoms.5,6
Although surgical bypass previously remained the gold
tandard treatment for severe symptoms related to lower
xtremity PAD, comorbidities associated with atheroscle-
otic disease often deem these procedures excessively high-
isk.7 Over the last decade, endovascular treatment for
ymptomatic occlusive PAD has emerged as frontline ther-
py with proven safety and efficacy, especially in high-
perative-risk patients.8 However, uncertainty persists re-
arding the best type of endovascular treatment strategy for
ymptomatic patients with SFA atherosclerotic disease, es-
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January 201338 Kiguchi et alpercutaneous transluminal angioplasty with selective use of
nitinol stents vs routine use of nitinol stents.
In addition, limited data are available on the patterns of
recurrence between these two endovascular treatment
strategies. This report examines the recurrence patterns of
SFA disease between routine vs selective stenting undergo-
ing endovascular reinterventions.
METHODS
Patients. All patients who underwent endovascular
treatment for native SFA and femoropopliteal arterial oc-
clusive disease between June 2003 and July 2010 were
retrospectively identified from prospectively maintained
physician databases. During the study period, 746 endovas-
cular procedures were performed in the femoropopliteal
arterial segment in 477 patients. Endovascular strategy of
routine vs selective stenting for each individual patient was
dictated by the attending surgeon’s preference. Preference
to routine vs selective stenting was not exclusive, however.
Findings at the time of angiography requiring necessary
secondary stenting regardless of stenting preference in-
cluded residual stenosis 30%, presence of a flow-limiting
dissection, or persistently suboptimal results after multiple
balloon inflations. Therefore, assignment to routine or
selective stenting was nonrandom due to surgeon prefer-
ence and indications for secondary stenting, but statistical
tests demonstrate that this did not create significant differ-
ences in demographic characteristics.
Patient data collected included demographic informa-
tion, time to and indication for reintervention for recurrent
symptoms (eg, claudication, rest pain), decrease in ankle-
brachial index (ABI)0.15, or duplex documentation of a
significant (80%) restenosis,9 and use of adjuvant medical
therapy. All angiograms and corresponding reports were
reviewed by independent vascular surgeons blind to the
stenting classification to determine anatomic features of the
lesions, TransAtlantic Inter-Society Consensus (TASC) II
classification of initial lesions, calcification scores, selective
vs routine stenting, location of stenosis, and the status of
the runoff vessels.
Definitions and classifications. Prior tobacco use was
defined as a history of regular tobacco use for 1 year.
Current tobacco use was defined as tobacco use at the time
of intervention. Indications for intervention were classified
as disabling claudication (Rutherford classification 2) or
critical limb ischemia (Rutherford classification 3-6).
Chronic renal insufficiency was defined as a serum creati-
nine level of 1.5 mg/dL, including those requiring he-
modialysis. The TASC II classification of femoral popliteal
lesions was used.10
Each primary intervention in the database was classified
as routine vs selective stenting according to angiographic
findings. Routine stenting (group RS) was defined as treat-
ment of any SFA or femoropopliteal segment, or both, that
received angioplasty and stenting. Selective stenting (group
SS) was defined as treatment of any SFA or femoropopliteal
segment, or both, that underwent angioplasty only or tartial stenting of the angioplastied segments, depending
n the severity of the recoil stenosis or dissection.
Reintervention was defined as the need for endovascular
eintervention, surgical bypass, amputation, or asymptomatic
cclusion diagnosed by surveillance duplex imaging. Recur-
ence patterns were classified as prior intervention site, mar-
inal, or de novo by angiographic evidence (Fig). Prior inter-
ention sites include in-stent or previously angioplastied
esions without placement of a stent. Marginal recurrence
as defined by disease at the margins of the previously
laced stent. De novo lesions were new diseased areas not
reviously treated or identified. Runoff vessels were classi-
ed as good, moderate, or poor by angiographic evidence
s assessed by three independent vascular surgery reviewers.
alcification was classified as none, mild, moderate, or
evere by angiographic evidence assessed by three indepen-
ent vascular surgery reviewers. Initial total occlusion was
efined as absence of arterial flow on initial angiogram.
Procedures. The patients were treated initially with bal-
oon angioplasty or stenting (nitinol based self-expanding
tent), or both, at the University of Pittsburgh Medical
enter by a multidisciplinary group of vascular surgeons
nd interventional radiologists in a fixed-imaging hybrid
perating room or in the interventional angiography
uite. Access was performed through the common femoral
rtery through a contralateral retrograde approach or an
psilateral antegrade approach using 6F sheaths. Standard
ortograms and lower extremity runoff angiograms were
erformed on all patients.
Interventions were performed after the administration
f unfractionated intravenous heparin, dosed 40 to 100
/kg. Balloon angioplasty was performed with nominal
nflations for a minimum of 1minute. Stents were deployed
or flow-limiting dissections. Self-expanding nitinol stents
Absolute, Abbott Vascular, Santa Clara, Calif; Smart, Cor-
is Endovascular, Warren, NJ; Sentinol, Boston Scientific,
atick, Mass; Protégé, ev3, Plymouth, Minn; and Lu-
inexx, Bard, Tempe, Ariz) and Viabahn covered stents
W. L. Gore and Associates, Flagstaff, Ariz) and their use in
elective vs routine stenting after angioplasty were selected
t the discretion of the attending surgeon.
Patients were given a 300-mg loading dose of clopid-
grel immediately after an intervention (unless the patient
as already taking the medication) and subsequently main-
ained on 75-mg daily for a minimum of 6months. Patients
ntolerant of clopidogrel were given aspirin (325 mg) im-
ediately after an intervention and subsequently main-
ained on the same dosage daily.
Follow-up. Patients were seen in office visit follow-up
t 1, 3, and 6 months, and thereafter every 6 months after
heir procedure with ABIs or complete arterial duplex
ltrasound imaging, or both. Patients with recurrent symp-
oms, decrease in ABI (0.2), or asymptomatic evidence of
estenosis (80%) on duplex imaging (as previous de-
cribed by our group) underwent reintervention.9
End points. The primary end point for the study was
ecurrence pattern of endovascular reinterventions between
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Volume 57, Number 1 Kiguchi et al 39points included total reintervention rates, time to recur-
rence, TASC II classification, runoff, and calcification of
endovascular reintervention sites between the two groups.
Statistical analysis. Advanced statistical analysis from
the Clinical and Translational Science Institute at the Uni-
versity of Pittsburgh was performed using R 2.13.1 soft-
ware (R Foundation for Statistical Computing, Vienna,
Austria). Differences in age and time to recurrence and
reintervention between selective and routine stenting
groups were calculated using the Mann-Whitney test.
Comparison of demographics, TASC class, recurrence pat-
tern, runoff, stent type, and calcification scores between the
two groups were performed using the Fisher exact test.
Statistical significance was defined as P  .05. Individual
limbs were counted as separate procedures, but random
selection was used to exclude one leg for patients who had
interventions on both legs to maintain the independence
required of the statistical analyses.
RESULTS
Patient population. Patients were considered appro-
priate for initial endovascular therapy due to their short
segments of disease, as promoted by the TASC II consensus
document or due to the high operative risk profile of the
patient, limiting peripheral bypass alternatives.10 None of
the patients treated needed concomitant inflow procedures
or femoropopliteal bypass for multisegmental or long le-
sions of disease not appropriate for endovascular interven-
tion.10,11
During the study period, 746 endovascular procedures
Fig. Recurrence types and location in the superficial femo
(B) in stent; (C) marginal.were performed in the femoropopliteal arterial segment in t77 patients; of these, 299 (40.1%) were treated with
elective stenting (SS group) and 447 (59.9%) were treated
ith routine stenting (RS group). Of all initial interven-
ions, 182 endovascular reinterventions in 165 patients for
ecurrent femoropopliteal lesions were identified, compris-
ng 70 in group SS and 95 in group RS. No significant
ifferences were identified between the cohorts in gender,
omorbidities, and indication for intervention; thus, non-
andom assignment to these two groups did not produce
ny systematic differences in these variables (Table I).
The rates of disabling claudication and critical limb
schemia as indications for primary intervention were simi-
ar between the two groups. Of patients who subsequently
nderwent endovascular reinterventions, 67.1% and 68.4%
f SS and RS patients, respectively, were classified as having
laudication, and 31.4% and 30.5% of SS and RS patients,
espectively, were classified as having critical limb ischemia.
obacco use, hypertension, and hyperlipidemia were com-
on in both cohorts.
Types of stent. Each stent type for all primary proce-
ures was analyzed independently, excluding any missing
alues for that stent only. There was a significantly higher
ate of use of each stent, excluding Viabahn and Luminexx,
n the SS group compared with the RS group (Table II).
Follow-up. After their primary intervention, 70 pa-
ients were lost to follow-up, with no clinic appointments
r hospitalizations recorded at our institution, and were
xcluded from calculations of mean and median follow-up
urations. The mean and median duration of follow-up for
ll primary interventions were 21.1 and 17 months, respec-
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January 201340 Kiguchi et alprimary interventions that did not require a reintervention
were 18.3 and 11.7 months, respectively; the mean and
median duration of follow-up for reinterventions, includ-
ing endovascular reinterventions, occlusions, bypasses, and
amputations, were 25.1 and 22.7 months, respectively. No
significant differences were seen between the RS and SS
groups.
Outcomes. The absolute reintervention rate of the
477 patients, including need for bypass or amputation, or
both, as well as asymptomatic occlusion was 36.5% (group
SS, 42.9%; group RS, 33.1%; P  .04), indicating a signif-
icantly higher reintervention rate for the selective stenting





(n  70) (n  95)
Age, years 71.6 (42.1-89.8) 71.5 (37.0-88.5) .82
Female sex 34/70 (48.6) 37/95 (38.9) .27
Tobacco use
Prior 50/70 (71.5) 70/95 (73.7) .86
Current 17/70 (24.3) 35/95 (36.8) .09
Claudication 47/70 (67.1) 65/95 (68.4) .87
Limb salvage 22/70 (31.4) 29/95 (30.5) 1.0
MI 19/70 (27.1) 22/95 (23.2) .59
Hypertension 61/70 (87.1) 75/95 (78.9) .22
Heart disease 8/70 (11.4) 5/95 (5.3) .16
CHF 11/70 (15.7) 16/95 (16.8) 1.0
CAD 46/70 (65.7) 52/95 (54.7) .20
CRI 17/70 (24.3) 23/95 (24.2) 1.0
CVA 15/70 (21.4) 23/95 (24.2) .71
Hyperlipidemia 45/70 (64.3) 59/95 (62.1) .87
Diabetes mellitus 32/70 (45.7) 45/95 (47.4) .88
Medication
Statin 46/70 (65.7) 50/95 (52.6) .11
Plavix 34/66 (51.5) 36/86 (41.9) .25
CAD, Coronary artery disease; CHF, congestive heart failure; CRI, chronic
renal insufficiency;CVA, cerebrovascular disease;MI,myocardial infarction.
aContinuous data shown as median (absolute range) and categoric data as
number (%).





between RS and SS
Smarta 38.75 SS  RSb
Absolutec 7.72 SS  RSb
Sentinold 16.24 SS  RSb
Protégée 31.31 SS  RSb
Viabahnf 0.79 . . .
Luminexxg 0.20 . . .
RS, Routine stenting; SS, selective stenting.
aCordis Endovascular, Warren, NJ.
bP  .01 for all differences in use.
cAbbott Vascular, Santa Clara, Calif.
dBoston Scientific, Natick, Mass.
eev3, Plymouth, Minn.
fW. L. Gore and Associates, Flagstaff, Ariz.
gBard, Tempe, Ariz.group. The 30-day failure rate was determined by identify- flng reinterventions, asymptomatic and symptomatic occlu-
ions, or amputation 30 days of primary endovascular
nterventions and was 3.1% (5/163) and 2.5% (8/314) for
elective and routine stenting, respectively.
Examination of the subset of patients who underwent
ndovascular reinterventions required a random exclusion
f one limb in the analysis in the 17 patients who had
ndovascular reinterventions in both limbs, to uphold the
ssumption of independence between observations. Abso-
ute, Smart, Sentinol, and Protégé stents were significantly
sed more often in routine stenting compared with selec-
ive stenting (P  .05). All stents were 6 mm in diameter,
ith the exception of a few 7-mm stents.
No significant differences were identified between the
ohorts in TASC II lesion classification (P  .41), runoff
lassification (P  .59), and calcification score (P  .51).
Median time to endovascular reintervention was 245.5
ays (range, 18-1078) for the SS group and 289.0 days
range, 27-2022) for the RS group (P  .07). The lower
imit within the range of time to endovascular reinterven-
ion in each cohort (ie, 18 and 27 days) represents missed
esions or stent failures, resulting in occlusion.
There were no significant recurrence patterns in endo-
ascular reinterventions. Endovascular reintervention at
he prior intervention site was almost evenly distributed
etween the two stenting groups (82.9% vs 80.0%; P 
69). Marginal disease recurrence trended toward a more
requent occurrence in routine stenting patients (25.7% vs
7.9%; P .13), but this difference was not significant. De
ovo recurrence trended toward occurringmore frequently
n selective stenting patients (50.0% vs 34.7%; P .06), but
urther study would be required to confirm this trend
ecause it was not quite statistically significant (Table III).
The number of eventual amputations, bypasses, and
cclusions within this subset was 17.2% (group SS, 15.7%;
roup RS, 18.3%; P  .69). Specifically, the SS group had
our occlusions, five bypasses, and two amputations; the RR
roup had five occlusions, 12 bypasses, and two amputa-
ions.
ISCUSSION
Percutaneous transluminal angioplasty as an alternative
o surgical bypass to revascularize the SFA has reported
nitial technical success rates of 95%, with low complica-
ion rates.11-15 Furthermore, most of these procedures can
e performed on an outpatient basis, are therefore more
ost-efficient than traditional bypass, and have minimal
mpact on functional status.16,17
One of the controversial aspects of percutaneous
ransluminal intervention of femoropopliteal disease, how-
ver, is the relative role of routine vs selective stenting for
uch lesions. Early use of balloon-expandable stents failed
o demonstrate any restenosis benefit over angioplasty
lone in randomized controlled clinical trials.18,19 Ran-
omized controlled trials of the second-generation, self-
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Volume 57, Number 1 Kiguchi et al 41In the Femoral Artery Stenting Trial (FAST), claudi-
cant patients with TASC II A lesions were randomized to
similar groups between primary stenting and angioplasty
alone. No difference in 1-year primary patency rates was
shown between the two cohorts (61.4% angioplasty alone
vs 68.3% routine stenting; P  .38).13 Late outcomes of
balloon angioplasty and angioplasty with selective stenting
for SFA disease yielded equivalent results when stratified
by indications of critical limb ischemia and claudication.
However, stenting provided better primary patency in
patients with more complex disease (ie, TASC II C and D
lesions).20
In contrast, The Randomized Study Comparing the
Edwards Self-Expanding Lifestent vs Angioplasty Alone in
Lesions Involving The SFA and/or Proximal Popliteal
Artery (RESILIENT) trial demonstrated 1-year duplex
ultrasound-derived primary patency was higher for routine
stenting than plain angioplasty of TASC II A lesions in
patients with claudication (81% routine stenting vs 36.7
angioplasty alone; P .1). It is noted, however, that 40% of
Table III. Recurrence patterns
Variablea
Selective Nonselective
P(n  70 legs) (n  95 legs)
Recurrence time,
days 245.5 (18-1078) 289.0 (27-2022) .07
TASC
A 18/69 (26.1) 17/94 (18.1) .41
B 17/69 (24.6) 33/94 (35.1)
C 13/69 (18.8) 19/94 (20.2)
D 21/69 (30.4) 25/94 (26.6)
Recurrence pattern
Prior intervention
site 58/70 (82.9) 76/95 (80.0) .69
Marginal 18/70 (25.7) 36/95 (37.9) .13
De novo 35/70 (50.0) 33/95 (34.7) .06
Runoff
Good 30/70 (42.9) 46/95 (48.4) .59
Compromised 29/70 (41.4) 32/95 (33.7)
Poor 11/70 (15.7) 17/95 (17.9)
Calcification
None 6/70 (8.6) 12/95 (12.6) .51
Mild 30/70 (42.9) 34/95 (35.8)
Moderate 22/70 (31.4) 37/95 (39.0)
Severe 12/70 (17.1%) 12/95 (12.6)
Type of stent
Smartb 12/70 (17.1) 30/95 (31.6) .05
Absolutec 10/70 (14.3) 7/95 (7.4) .20
Sentinold 5/70 (7.1) 21/95 (22.1) .01
Protégée 16/70 (22.9) 41/95 (43.2) .01
Viabahnf or
Luminexxg 0/70 (0.0) 1/95 (1.1) . . .
TASC, TransAtlantic Inter-Society Consensus.
aContinuous data are shown as median (absolute range) and categoric
data as number (%).
bCordis Endovascular, Warren, NJ.
cAbbott Vascular, Santa Clara, Calif.
dBoston Scientific, Natick, Mass.
eev3, Plymouth, Minn.
fW. L. Gore and Associates, Flagstaff, Ariz.
gBard, Tempe, Ariz.patients who were initially randomized to the angioplasty flone arm were considered immediate failures of primary
atency due to residual stenosis and crossed over to the
outine stenting arm, resulting in a large bias in the intent-
o-treat analysis against angioplasty alone.21
The randomized Balloon Angioplasty vs Stenting
ith Nitinol Stents in the Superficial Femoral Artery
ABSOLUTE) trial compared primary stenting and balloon
ngioplasty with selective stenting with Rutherford classes 3
o 5 disease and TASC II A and B lesions. Results reported
1-year primary patency of 63% with routine stenting vs
7% with selective stenting (P .01). A bailout rate of 32%
as seen in this trial for those randomized to the angio-
lasty with selective stenting treatment who required rou-
ine stenting due to persistent dissection or refractory ste-
osis.12 At 2-year follow-up, routine stenting for treatment
f SFA lesions sustained a duplex and clinical benefit com-
ared with balloon angioplasty with optional stenting.22
The patency rates of the ABSOLUTE andRESILIENT
rials lent support to the efficacy and durability of routine
ompared with selective stenting. However, when the pa-
ients who crossed over to the routine stenting arm after
rimary failure of angioplasty were excluded to mitigate the
ntention to treat bias, the primary patency rates of rou-
ine vs selective stenting groups of the ABSOLUTE and
ESILIENT trials were comparable with the FAST study. In
his single-center series, the overall recurrence rate was
6.5%. The recurrence rate was higher in the SS group
42.9%) than in the RS group (33.1%; P .04); however, a
urther examination of these recurrences in the SS group
howed an unexpected pattern. The recurrence pattern
ifference of de novo lesions was close to significantly
ifferent between the SS and RS group, with increased
requency among SS patients, and there was no difference
n prior intervention and marginal lesions between the SS
nd RS groups. Thus, de novo lesions—not at the site of
rimary intervention—appeared to be more common le-
ions of recurrence among SS patients.
In the current study that included 165 patients (70 SS
nd 95 RS) with endovascular reinterventions, time to
ecurrence between the two groups was not significantly
ifferent (P  .07). Although the overall intervention rate
as 36.5%, with recurrence noted in 42.9% of patients in
he SS group vs 33.1% in RS patients (P  .04), neither
roup tended to have more asymptomatic occlusions, by-
asses, or amputations (15.7% vs 18.3%; P .69). It could
e hypothesized that when reinterventions are necessary,
S may require more endovascular reinterventions, whereas
S may require surgical reinterventions.
All TASC II lesions were included in this current study,
hereas only TASC II A and B lesions were enrolled in
reviously reported randomized trials. Although endovas-
ular interventions for TASC II B and C lesions are associ-
ted with restenosis and occlusion rates that are at least
omparable to those of open femoropopliteal bypass sur-
ery,11 the inclusion of TASC II C and D lesions in this
tudy led to diseased lesions that otherwise required open
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tions, among others.
Treating these more diseased lesions tends to require
routine stenting,23 and lesion severity has been shown to
predict outcome after endovascular treatment of femoro-
popliteal lesions,10 and hence, when endovascular interven-
tion fails, these patients are back to open surgical options.
Influenced by the high-risk profile and life-expectancy lim-
itations seen in PAD patients and the morbidity and mor-
tality of leg bypass surgery, the “endovascular-first” posture
for most patients who require revascularization may have
included more advanced TASC II lesions that otherwise
would have been treated by open peripheral bypass, which
ultimately affected the overall recurrence rate between the
selective and routine stenting groups.
Although no significant difference was seen in the
patterns of endovascular reinterventions in our current
study, it is notable that disease at the prior intervention site
was similar between the SS and RS groups (82.9% vs 80.0%;
P  .69). The previous sites treated with routine stenting
were as likely to be durable than angioplasty without stent-
ing. De novo disease recurrence trended toward being
more common in the SS cohort than in the RS cohort
(50.0% vs 34.7%; P .06). Data trends suggest SS patients
who had endovascular reinterventions may have had a
higher severe calcification classification and TASC II D
lesions than the RS patients, potentially contributing to the
increased likelihood to develop clinically significant de
novo lesions. However, these aforementioned trends were
not statistically significant and would require further study
to confirm.
Data from multiple randomized trials and meta-analyses
have been inconclusive with regard to the durability of
routine stenting compared with selective stenting after
angioplasty.24 Although the total recurrence rate was
greater for selective stenting compared with routine stent-
ing, examining patterns of recurrence in endovascular rein-
tervention in this current study has demonstrated that
endovascular reinterventions do not occur at the site of
prior intervention.
This study has a number of limitations. The most
important limitation is its retrospective nature and being
limited by single-institution data. Patient selection and
treatment modality were at the discretion of the operating
surgeon and not systematically protocoled. The subjective
classification of calcification score and runoff scores to gross
categories also limits the accuracy of predictive factors.
Reliance on surgeon compliance with angiographic docu-
mentation limits accuracy. Our intent was to characterize
the length of the recurrent lesions, including specific loca-
tion of disease recurrence (ie, angioplasty at SFA origin),
but without standardized angiography images from all
participating surgeons, it was difficult to assess measure-
ments consistently; characterizations of recurrence treated
by endovascular means, such as severity of restenosis and
methods used to retreat lesions, are being currently inves-
tigated. Further analysis of this prospectively maintained
database will provide details on the angiographies of pa-ients who did not receive endovascular reinterventions,
ut rather, underwent bypass grafts, amputations, or
symptomatic reocclusions who underwent angiography
ue to recurrence phenomena; the patterns and effective-
ess (patency and symptomatic relief) of multiple endovas-
ular reinterventions will be analyzed to assess secondary-
ssisted patency rates between the two groups whether by
outine or selective stenting selection. Measured outcomes
f durability of endovascular procedures remain difficult to
efine, but longer-term and better adherence to standard-
zed follow-up is necessary to determine their patency.
ONCLUSIONS
In this single-center retrospective study involving a
elatively large number of patients, we found a significant
ifference in the incidence of recurrence requiring reinter-
ention between patients treated with selective stenting and
outine stenting for femoropopliteal disease. Analysis of
ndovascular reinterventions, however, reveals no signifi-
ant difference in recurrence time or recurrence pattern
etween the two groups. No significant differences in time
o recurrence, TASC II classification, runoff, and calcifica-
ion of endovascular reinterventions between the end
oints of the two groups were identified. We believe these
ata make a compelling case for a prospective study to
valuate further the roles of routine and selective stenting in
ymptomatic femoropopliteal PAD.
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